CD274 Amplification

CI-VAR-00000253Explore in graph →CIViC 4971

Curated evidence

Evidence by cancer (1 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–1 of 1 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Triple-Negative Breast Carcinoma1
CD274 Amplification	Durvalumab	Predictive	B	Supports Sensitivity Response	3	submitted	EID12054 Sensitivity to durvalumab was tested in patients with triple-negative breast cancer (TNBC) harbouring CD274 gain/amplification. CD274 amplifications were noted in 42% (n=23) of the TNBC samples. Patie… (full text at CIViC) PMID 33462450 · Bachelot et al., 2021 · Open in CIViC	civic

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.